Literature DB >> 2072119

Characterisation of dystrophin in carriers of Duchenne muscular dystrophy.

A Clerk1, E Rodillo, J Z Heckmatt, V Dubowitz, P N Strong, C A Sewry.   

Abstract

Dystrophin, the protein product of the Duchenne muscular dystrophy (DMD) gene, was studied in needle biopsy samples taken from the quadriceps muscle of 15 asymptomatic carriers of DMD (13 adults and 2 young girls) and one symptomatic adult carrier. Antibodies to N- and C-terminal regions of dystrophin were used for both Western blot analysis and immunocytochemistry and a monoclonal antibody to beta-spectrin used to assess membrane integrity. All asymptomatic adult carriers showed some abnormality in dystrophin immunostaining but very few negative fibres were present. A clear mosaic of dystrophin positive and negative fibres was seen only in the adult symptomatic carrier and the two young girls. On a Western blot, all carriers studied had dystrophin of normal molecular weight, but most had reduced abundance. In adult carriers, the amount of dystrophin relative to normal controls varied, but it was unrelated to age, serum creatine kinase (CK) levels or to the degree of pathology. Carriers with normal CK showed abnormalities in dystrophin expression. The dystrophin immunoblotting profile of the 2 young girls was very similar to that of their mothers, but the mosaic pattern of immunostaining was not apparent in the older carriers. In conclusion, dystrophin immunostaining and Western blot analysis of biopsy samples from asymptomatic carriers is often abnormal and they may be useful additional aids for establishing carrier status, particularly in younger girls.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2072119     DOI: 10.1016/0022-510x(91)90069-j

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

1.  A model to estimate the expression of the dystrophin gene in muscle from female Becker muscular dystrophy carriers.

Authors:  M Vainzof; M R Passos-Bueno; R C Pavanello; R Schreiber; M Zatz
Journal:  J Med Genet       Date:  1992-07       Impact factor: 6.318

2.  The clinical and molecular genetic approach to Duchenne and Becker muscular dystrophy: an updated protocol.

Authors:  A J van Essen; A L Kneppers; A H van der Hout; H Scheffer; I B Ginjaar; L P ten Kate; G J van Ommen; C H Buys; E Bakker
Journal:  J Med Genet       Date:  1997-10       Impact factor: 6.318

3.  Detection of new paternal dystrophin gene mutations in isolated cases of dystrophinopathy in females.

Authors:  E Pegoraro; R N Schimke; K Arahata; Y Hayashi; H Stern; H Marks; M R Glasberg; J E Carroll; J W Taber; H B Wessel
Journal:  Am J Hum Genet       Date:  1994-06       Impact factor: 11.025

4.  Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis.

Authors:  L V Nicholson; M A Johnson; K M Bushby; D Gardner-Medwin; A Curtis; I B Ginjaar; J T den Dunnen; J L Welch; T J Butler; E Bakker
Journal:  J Med Genet       Date:  1993-09       Impact factor: 6.318

5.  DMD carrier model with mosaic dystrophin expression in the heart reveals complex vulnerability to myocardial injury.

Authors:  Tatyana A Meyers; Jackie A Heitzman; DeWayne Townsend
Journal:  Hum Mol Genet       Date:  2020-04-15       Impact factor: 6.150

6.  Dystrophin analysis using a panel of anti-dystrophin antibodies in Duchenne and Becker muscular dystrophy.

Authors:  F Muntoni; A Mateddu; C Cianchetti; M G Marrosu; A Clerk; M Cau; R Congiu; A Cao; M A Melis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-01       Impact factor: 10.154

7.  From proteins to genes: immunoanalysis in the diagnosis of muscular dystrophies.

Authors:  Rita Barresi
Journal:  Skelet Muscle       Date:  2011-06-24       Impact factor: 4.912

8.  Dystrophin abnormalities in Duchenne and Becker dystrophy carriers: correlation with cytoskeletal proteins and myosins.

Authors:  M Mora; L Morandi; A Piccinelli; E Gussoni; M Gebbia; F Blasevich; F Dworzak; F Cornelio
Journal:  J Neurol       Date:  1993-09       Impact factor: 4.849

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.